- Record: found
- Abstract: not found
- Article: not found
A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer
EE Vokes, FP Worden, D Adkins, SE Kochanny, DR Adkins, Everett E. Vokes, Francis P. Worden, Douglas Adkins, Julie E. Bauman, Dean Lim, Ammar Sukari, Krishna A. Rao, Stephanie Ann Wagner, Kelly Curtis, Barbara Gitlitz, Katharine Price, James Wade, Victoria M. Villaflor, Jonas de Souza, Theodore Karrison, Walter Stadler, Tanguy Y. Seiwert, E. VOKES, F. Worden, J. Bauman, D. LIM, A Sukari, FPA Worden, D Bauman, JE Lim, D Sukari, Ammar, KAW Rao
2015
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.